Loading organizations...
Key people at Kingray Capital.
Kingray Capital is a private equity investment firm based in China, primarily focused on engaging in private equity investment business across various stages and sectors. The firm's operational model centers on identifying and deploying capital into private companies, though specific investment criteria, target industries, or geographic focus beyond China are not publicly detailed. Key financial metrics such as asset under management (AUM), total funding raised, or the firm's employee headcount are not disclosed in available public records. Information regarding lead investors, notable portfolio companies, or significant customer relationships remains private, consistent with the operational discretion often exercised by private investment entities. Kingray Capital commenced its operations in 2018; the names of its founders are not publicly available. Its business model centers on engages in private equity investments, specific revenue or funding details unknown.
Key people at Kingray Capital.
Kingray Capital has 2 tracked investments across 2 companies. The latest tracked deal is $20.0M Pre-Series A in Epigenic Therapeutics in August 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 8, 2022 | Epigenic Therapeutics | $20.0M Pre-Series A | — | FountainBridge Capital, Michael Xue, Trinity Innovation Fund |
| Jan 5, 2022 | Atom Bioscience & Pharmaceutical | $45.0M Series C | Yuhang Teng, Huang Pu | Efung Capital, Hongshan Capital Group (Sequoia Capital China), Kaitai Capital, Livzon Pharmaceutical Group, Unifortune Investment Holdings Group |